GLP-1 weight loss results: what TikTok gets right and wrong

What did @honeybthatsme actually say?

The creator addresses a common criticism head-on: "when you get off of it, you're gonna gain all the weight." She says she's maintained her weight at 126-128 lbs after going off her previous dosing schedule, feels energized, and now takes her shot "only once a month" through a service called Freya. She's framing her experience as proof that the weight-regain narrative is overblown, at least in her case.

It's a relatable, confident counter to one of the most repeated complaints about GLP-1 medications. But personal anecdotes, even honest ones, aren't the same as evidence. Let's look at what the research actually says before anyone takes her maintenance story as a roadmap.

Does the science back this up?

On the weight-regain question, the science is pretty blunt: yes, most people do regain significant weight after stopping GLP-1 agonists. The STEP 4 trial (Rubino et al., 2021, JAMA) found that participants who discontinued semaglutide regained about two-thirds of their prior weight loss within one year. That's not a fringe finding, it's the most-cited data on this exact topic.

That said, individual outcomes vary. Factors like how long someone used the medication, whether they made lifestyle changes, their starting metabolic profile, and how their appetite regulation responds all play a role. Some people do maintain more of their loss than others. The creator's experience isn't impossible, but it's not typical either, and presenting it without that context can mislead a 791K-view audience into thinking discontinuation is lower-risk than the data suggests.

On the "once a month" dosing claim: standard FDA-approved semaglutide protocols (Wegovy, Ozempic) are weekly injections. A monthly injection schedule is not a recognized clinical protocol for any approved GLP-1 product. This could refer to a compounded formulation, but compounded drugs are not equivalent to brand-name medications in bioavailability or regulatory oversight.

What did they get wrong (or right)?

Credit where it's due: she doesn't claim she's cured anything. She's reporting her personal weight on a specific morning, which is honest and appropriately scoped. Saying "I am still 128" is just a personal data point, not a medical claim.

Where she goes wrong is the implicit argument: her maintained weight after stopping (or reducing) GLP-1 therapy means the weight-regain concern is exaggerated. That's not what her single data point shows. She may be in a short post-discontinuation window, she may be on a reduced but ongoing dose monthly, or she may genuinely be an outlier. None of those possibilities are addressed.

The "once a month" shot detail is the most clinically significant flag here. If this is a compounded GLP-1 product marketed as a monthly long-acting formulation, that product has not gone through the same clinical trials as weekly semaglutide. Freya, the service she's endorsing, appears to offer compounded medications. Compounded formulations are not FDA-approved and cannot be treated as interchangeable with brand-name GLP-1 drugs.

What should you actually know?

GLP-1 medications work, and the weight-regain data after stopping them is not a scandal, it reflects the biology. Obesity involves hormonal and neurological regulation that these drugs temporarily modify. When you stop, those systems don't stay modified. Wilding et al. (2022, Diabetes, Obesity and Metabolism) confirmed that the metabolic benefits of semaglutide largely reverse within months of stopping.

This doesn't mean GLP-1 drugs aren't worth using. It means they're closer to a long-term management tool than a short course of treatment, for most people. Some individuals with lower starting BMIs or who've made substantial lifestyle changes may maintain more of their results, but that's the exception, not the rule.

If you're considering a monthly injection protocol through a telehealth platform offering compounded GLP-1 formulations, ask hard questions: What is the active compound? What is the half-life? Has the dosing interval been studied? "Once a month" sounds convenient, but it is not a validated protocol backed by the same evidence base as weekly injections.

• Weight regain after stopping semaglutide is well-documented and affects most users within 12 months.
• Individual results like the creator's are real but not representative of population-level outcomes.
• Compounded GLP-1 formulations are not FDA-approved and are not equivalent to brand-name drugs.
• Monthly injection schedules for GLP-1 drugs are not supported by current clinical trial data.